


Dolutegravir + 2 NRTIs versus Darunavir + RTV + 2 NRTIs
FLAMINGO

Dolutegravir + 2 NRTIs versus Darunavir + RTV + 2 NRTIs

FLAMINGO: Study Design




*2 NRTIs = tenofovir-emtricitabine or abacavir-lamivudine (with negative HLA-B*5701 testing).

Dolutegravir + 2 NRTIs versus Darunavir + RTV + 2 NRTIs

FLAMINGO: Results


Week 48 Virologic Response, by Baseline HIV RNA Level



Dolutegravir + 2 NRTIs versus Darunavir + RTV + 2 NRTIs

FLAMINGO: Results


48 Week Virologic Outcomes (Modified Intent-to-Treat Analysis)



Dolutegravir + 2 NRTIs versus Darunavir + RTV + 2 NRTIs

FLAMINGO: Results

Week 48 Virologic Response, by Background Dual NRTI Therapy



Dolutegravir + 2 NRTIs versus Darunavir + RTV + 2 NRTIs

FLAMINGO: Common Adverse Events

Treatment Emergent Adverse Events in $\geq 5\%$ of Subjects in Either Arm		
	DTG + 2 NRTIs (n = 242)	DRV + RTV + 2 NRTIs (n = 242)
Dizziness	17%	29%
Nausea	16%	18%
Headache	15%	10%
Nasopharyngitis	9%	8%
Upper respiratory infection	5%	10%
Insomnia	7%	6%
Cough	5%	7%
Vomiting	6%	6%
Fatigue	6%	5%

Source: Clotet B, et al. Lancet. 2014;383:2222-31.

Dolutegravir + 2 NRTIs versus Darunavir + RTV + 2 NRTIs FLAMINGO: Common Adverse Events (continued)

Treatment Emergent Adverse Events in $\geq 5\%$ of Subjects in Either Arm		
	DTG + 2 NRTIs (n = 242)	DRV + RTV + 2 NRTIs (n = 242)
Pyrexia	5%	6%
Dizziness	6%	5%
Rash	4%	6%
Back Pain	4%	5%
Pharyngitis	3%	5%
Bronchitis	2%	5%
Sinusitis	2%	5%
Depression	5%	2%
Arthralgia	2%	5%

Source: Clotet B, et al. Lancet. 2014;383:2222-31.

Dolutegravir + 2 NRTIs versus Darunavir + RTV + 2 NRTIs FLAMINGO: Conclusions

Interpretation: “Once-daily dolutegravir was superior to once-daily darunavir plus ritonavir. Once-daily dolutegravir in combination with fixed-dose NRTIs represents an effective new treatment option for HIV-1-infected, treatment-naive patients.”

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling \$800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.

